Clywedog Therapeutics today announced positive final results from its Phase 1b study (ZE63-0302-0002) of balomenib, an investigational oral small-molecule menin inhibitor, in adults with type 2 diabetes. The study completed its last patient visit on 11 July 2026.

Clywedog Therapeutics announced the activation of all clinical centers and patient dosing in its multicenter, international Phase 1b randomized, double-blind, placebo-controlled clinical study evaluating balomenib, a novel oral menin inhibitor, in adults with type 2 diabetes mellitus (T2DM).

The combined company, Clywedog Therapeutics, will bring a portfolio that includes three differentiated, clinical stage product candidates which are being studied for the prevention/reversal of Type 1 and Type 2 Diabetes and the treatment of Celiac Disease.